Roche NimbleGen, Sigma-Aldrich Set Co-marketing Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Roche NimbleGen said today that it has aligned its chromatin immunoprecipitation-on-microarrays (ChIP-chip) with Sigma Aldrich's GenomePlex whole-genome amplification technology, and the companies will co-market the technologies together.

Researchers can use the two platforms together to study the genome for epigenetic interactions between DNA and DNA-binding proteins to find out what regions are transcriptionally active or repressed, and the mechanisms that regulate these processes, Roche said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.